CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013 CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013 Oss, Netherlands – 31 July 2024 – Citryll, a clinical-stage biotech...